Evofem Warns of Going‑Concern as Cash Hits Zero, Debt Soars; Aditxt Merger Pending

Evofem Biosciences, Inc. (NASDAQ: EVFM) - Quick read on what's happening inside

Reality check: Evofem is a commercial-stage women's health company running two marketed products (PHEXXI and SOLOSEC) but is under severe financial strain. Management is trying to grow revenue while negotiating heavy debt, related‑party financings and a pending merger with Aditxt. The SEC 10‑Q (quarter ended June 30, 2025) flags substantial doubt about the company's ability to continue as a going concern.

Key facts & figures (from the 10‑Q)
* Product sales, net - Three months ended June 30, 2025: $4,825 (thousands).
* Product sales, net - Six months ended June 30, 2025: $5,670 vs $7,763 in H1 2024 (down 27% year‑over‑year).
* Three months ended June 30, 2025 net loss: $(1,784). Six months net loss: $(828).
* Loss from operations, Q2 2025: $(1,251).
* Change vs prior year: Q2 product sales up 16% vs Q2 2024 ($4,160) - driven by adding SOLOSEC and higher WAC; but H1 2025 sales declined vs H1 2024.
* Total assets: $14,382. Total liabilities: $79,212. Stockholders' deficit: $(69,616).
* Working capital deficit: $64.9 million (management disclosure).
* Cash and cash equivalents per balance sheet shown as $0; restricted cash: $748 (end of period cash, cash equivalents and restricted cash = $748).
* Trade accounts receivable: $4,934 (down from $9,832 at 12/31/24). Inventories: $1,906.
* Intangible asset (SOLOSEC), net: $4,738 (down from $9,597 at 12/31/24) - amortization and fair‑value adjustments.
* Convertible notes / debt: Baker Notes outstanding principal + accrued interest ≈ $114.8M (fair‑value recorded $14.6M); Adjuvant Notes recorded $31.9M (principal net of issuance costs $22.5M + $9.4M accrued interest).
* Warrants & potential dilution: ~263.1 million warrants outstanding; common stock reserved for future issuance: 1,224,873,833 shares (includes purchase rights, convertible notes and preferred conversions).
* OTC listing activity: failed OTCQB minimum bid; moved to OTC Pink, then to OTCID (new basic reporting tier) on July 1, 2025.
* Number of common shares outstanding (Aug 9, 2025): 118,656,354.

What's working (positives on income statement / operations)
* Q2 product sales increased 16% YoY (addition of SOLOSEC + WAC increase and improved gross‑to‑net).
* Cost of goods sold decreased modestly in H1 (down 23% YoY) - partly due to end of Rush University royalty after patent expiry and lower PHEXXI volumes.
* Management reduced certain G&A and R&D cash expenses (G&A down ~17% YoY in both Q2 and H1).
* Non‑cash adjustments (fair value changes) provided some positive other income in H1 (change in fair value of instruments contributed gains in earlier periods).

Problems to focus on (negatives on income statement & balance sheet)
* Net loss persists: Q2 net loss $(1.78M). H1 still loss‑making (though H1 2025 loss smaller than H1 2024).
* Volatility in "other income (expense)": fair‑value swings of derivatives/notes create noisy non‑cash swings - makes underlying cash profitability hard to see.
* Revenue mix: Q2 lift versus Q2 2024 masks H1 decline (H1 2025 sales $5.67M vs $7.76M prior year) - inconsistent top‑line momentum.
* Very weak liquidity: effectively no unrestricted cash ($0 reported), only $748k restricted; operating cash used $(2.36M) in H1 2025; management says cash is insufficient for 12 months without new funding.
* Heavy debt and contingent liabilities: large convertible notes (Baker, Adjuvant, SSNs, Aditxt), contingent SOLOSEC payments, and lease/trade payables - total liabilities far exceed assets.
* Dilution risk: massive outstanding purchase rights, warrants and convertible instruments that could dilute holders dramatically if converted/exercised.
* Going concern: management and auditors disclose substantial doubt about ability to continue as a going concern - must raise cash or restructure debt.
* Customer concentration: three largest customers ~80% of gross product sales in Q2 and ~72% in H1; credit concentration risk remains high.

Internal dynamics / governance & related parties
* Aditxt is a major related‑party investor and potential acquirer (Merger Agreement amended multiple times). Company issued Aditxt Notes and warrants in Apr/Jun 2025 (net proceeds ≈ $2.4M).
* Baker/Future Pak default notices and complex Baker Notes amendments create litigation and enforcement risk; Company disputes some default claims and has repurchase mechanics/repurchase price schedules in place.
* CEO (Saundra Pelletier) served on Aditxt board (appointed June 9, 2025) - potential related‑party / governance matters noted; she notified she will not stand for re‑election to Aditxt board (Aug 7, 2025).
* Management disclosed material weaknesses in internal control over financial reporting; remediation in process but not yet resolved.

Short take / investment‑facing summary
* The business has commercial traction (PHEXXI growth historically and SOLOSEC contribution), but cash is essentially depleted and liabilities dwarf assets. The company needs near‑term financing, debt restructuring, non‑dilutive licensing, or a completed merger to avoid liquidation risk.
* Financials are affected heavily by non‑cash fair‑value accounting on convertible instruments and purchase rights; that creates headline volatility separate from operating cash performance.
* Key risks to monitor: actual cash available vs restricted cash, outcome of Baker/Future Pak default notices, progress (and terms) of Aditxt merger/financings, and any further dilution from huge reserved share pool.

If you want, I can draft a 1‑page investor brief (bullet format) summarizing runway scenarios, dilution math, and the near‑term catalysts to watch (merger milestones, debt repayments, Pharma 1 licensing milestones, any equity or non‑dilutive funding).